Neuroscientists report a distinct role of touch receptors in treating chronic pain

People often experience the phenomenon of injuring a hand and feeling relief from vigorously shaking it. The mechanism behind this effect is fairly well explained by the "gate control theory" of Melzack and Wall, but it is somewhat more complicated.

Shaking your hand modifies the pain signals in the spinal cord in the superficial dorsal horn area, which are transmitted by Aδ and C fibers. This area is activated by pain signals, but there are other connections responsible for sensing touch (Aβ mechanoreceptors) and they can block the pain signals at this location. Therefore, this crosstalk between touch and pain neurons finally decides the noxious or non-noxious output depending on the type and duration of injury.

Chronic pain and its relevance

Chronic pain is a catastrophic disorder of the nervous system affecting more than 30% people worldwide, creating a significant socioeconomic burden. A prominent symptom of chronic pain is mechanical hyperalgesia, or increased pain triggered by mechanical stimuli. At present, effective non-opioid treatment for mechanical hyperalgesia is limited, reflecting a knowledge gap in its underlying mechanisms.

Complicated role of Aβ low threshold mechanoreceptors in pain

Aβ low-threshold mechanoreceptors (Aβ-LTMRs) are large-diameter, highly myelinated and fast-conducting primary somatosensory neurons, which normally mediate tactile, discriminative touch and vibration sensation.

Aβ-LTMRs are further divided into rapidly adapting (RA) and slowly adapting (SA) types based on their firing patterns in response to a sustained mechanical stimulus. At baseline conditions, co-activation of touch- and pain-sensing neurons inhibits the flow of nociceptive information, as proposed in the "gate control theory of pain."

Functions of Aβ-LTMRs in chronic pain have been of great interest but are controversial. On one hand, several studies suggested that Aβ-LTMRs may mediate mechanical hyperalgesia of chronic pain; some studies suggest that Aβ-LTMRs inhibit nociception even in chronic conditions. Rubbing or massaging a painful area of the skin, which presumably activates Aβ-LTMRs, attenuated pain in humans.

The spinal cord stimulator (SCS) and transcutaneous electrical nerve stimulation (TENS), which was developed based on the "gate control theory of pain" to target Aβ-LTMRs, are effective for treating chronic pain conditions, including neuropathic pain. Additional real-life therapy procedures, including massage therapy and electroacupuncture, presumably involve the activation of Aβ-LTMRs for their beneficial effects.

What may lead to the diverse role of Aβ low threshold mechanoreceptors in pain?

When comparing different studies and their results, we noticed two factors that likely contribute to the diverse outcomes of Aβ-LTMRs in transmitting mechanical hyperalgesia or in its alleviation.

The first consideration is the specificity of Aβ-LTMR manipulation and the functional readouts. Though pharmacological and mechanical/electrical stimuli can inhibit or activate Aβ-LTMRs, other types of nerve fibers are likely simultaneously affected as well. For genetic and optogenetic manipulations, few available mouse genetic tools are selective or show high preference for Aβ-LTMRs. In addition, it has been challenging to differentiate touch and nociception-associated reflex behavioral responses in animal studies.

The second consideration is whether Aβ-LTMRs are manipulated locally at the area affected by chronic pain or in a broad manner, including the unaffected Aβ-LTMRs, which may generate different sensory and behavioral outcomes.

To provide novel insight into this question, we used tools with improved specificity, including intersectional mouse genetics, opto-tagged electrophysiological recordings (in collaboration with Dr. Jianguo Gu's lab at University of Alabama at Birmingham), and optogenetic activation of Aβ-LTMRs, and performed a battery of behavioral tests to probe mouse mechanical and thermal sensations when Aβ-LTMRs were manipulated locally or globally.

We also took advantage of a high-speed imaging method to differentiate touch-related non-nociceptive behavior from nocifensive behaviors. Our study is published in the journal Nature Communications.

Major outcomes of the study

1. Mice with global ablation of Split^Cre-Aβ-LTMRs showed decreased sensitivity to gentle mechanical forces, increased mechanical nociception at baseline condition, and increased mechanical hyperalgesia in a chronic inflammatory pain model, suggesting that Aβ-LTMRs function to inhibit mechanical nociception and mechanical hyperalgesia.
2. Thermosensation was not affected by Aβ-LTMR manipulation, indicating that these afferents functioned in a modality-specific manner.
3. In reverse experiments, local optical activation of Split^Cre-Aβ-LTMRs at the hind paw triggered nocifensive responses in chronic inflammatory and neuropathic pain models. This suggests that activities of locally affected Aβ-LTMRs lead to nociception, likely contributing to mechanical hyperalgesia of chronic nociception.
4. Rapidly adapting mechanoreceptors in the glabrous skin following tissue inflammation fired more numbers of action potentials (displaying a slowly adapting-like property).
5. Global activation of Aβ-LTMRs at the dorsal column alleviated mechanical hyperalgesia in a chronic inflammatory pain model.

Conclusion

Together, the results of our study establish a model that Aβ-LTMRs play globally inhibitory but locally promoting roles for mechanical hyperalgesia. This model suggests a strategy: global activation plus local inhibition of Aβ-LTMRs for treating mechanical hyperalgesia of chronic pain. Some transcutaneous electrical nerve stimulation (TENS) strategies aim to target peripheral Aβ-LTMRs 2-3 dermatomes away from the injury site; their effects in alleviating pain were supported by several clinic trials. These practices and effects also align well with this study's results and model.

Finally, this model proposes a potentially more effective compound strategy to target Aβ-LTMRs for treating mechanical hyperalgesia and chronic pain: activating them globally or three to four dermatomes away from the injury site and combining with local inhibition of the affected Aβ-LTMRs.

—Mayank Gautam, Jianguo Gu and Wenqin Luo , Medical Xpress

This article was originally published on MedicalXpress Breaking News-and-Events.